Decreased initiation of usual activities in people with mild-to-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial

被引:24
|
作者
Cook, Cheryl [3 ,4 ]
Fay, Sherri [3 ,4 ]
Rockwood, Kenneth [1 ,2 ]
机构
[1] Dalhousie Univ, Div Geriatr Med, Halifax, NS B3H 2E1, Canada
[2] Capital Dist Hlth Author, Div Geriatr Med, Halifax, NS, Canada
[3] Capital Dist Hlth Author, Geriatr Med Res Unit, Halifax, NS, Canada
[4] Dalhousie Univ, Geriatr Med Res Unit, Halifax, NS B3H 2E1, Canada
基金
加拿大健康研究院;
关键词
initiation; Alzheimer's disease; galantamine; phenomenology;
D O I
10.1017/S1041610208007230
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Decreased initiation of activities is a common symptom in Alzheimer's disease (AD) and creates significant burden for carers, yet little is known about how patients, carers and treating physicians describe this problem. Methods: This is a secondary, qualitative analysis of video-recorded, semi-structured and open-ended interviews with the 130 community-dwelling patients with mild-to-moderate AD from the Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) study - a four-month, randomized, placebo-controlled trial of galantamine. Interviews were coded and organized using Atlas.ti. By applying a framework analysis approach, patient/carer descriptions of dementia-related decreased initiation of usual tasks and activities were categorized and summarized. Results: Decreased initiation of instrumental activities of daily living (IADLs) and/or leisure and social activities was reported in 85/130 patients at baseline, 71 (84%) of whom specifically targeted increased initiation as a goal of treatment. The most common manifestations of decreased initiation were initiating only with prompting (55%), and no longer initiating but willing to engage in the activity (42%; note that these groups can overlap). Many patients were also described as having less interest (44%) or impaired performance (34%) in the activity in which decreased initiation was noted. Coping strategies were employed by 69/85 carers, most commonly verbal prompts to begin an activity. Conclusion: Decreased initiation is a common and problematic symptom in people with mild-to-moderate Alzheimer's disease who seek treatment for dementia. Information offered voluntarily about interest in or ability to perform activities which are initiated less often gives additional data compared with routine questioning about initiation of function. This is a potentially rich area for the elucidation of disease and treatment effects.
引用
收藏
页码:952 / 963
页数:12
相关论文
共 50 条
  • [1] Verbal Repetition in People With Mild-to-Moderate Alzheimer Disease A Descriptive Analysis From the VISTA Clinical Trial
    Cook, Cheryl
    Fay, Sherri
    Rockwood, Kenneth
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2009, 23 (02): : 146 - 151
  • [2] Misplacing objects in mild to moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial
    Hamilton, L.
    Fay, S.
    Rockwood, K.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (09): : 960 - 965
  • [4] Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease
    Egan, Michael F.
    Kost, James
    Tariot, Pierre N.
    Aisen, Paul S.
    Cummings, Jeffrey L.
    Vellas, Bruno
    Sur, Cyrille
    Mukai, Yuki
    Voss, Tiffini
    Furtek, Christine
    Mahoney, Erin
    Mozley, Lyn Harper
    Vandenberghe, Rik
    Mo, Yi
    Michelson, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (18): : 1691 - 1703
  • [5] Nicergoline in the treatment of mild-to-moderate Alzheimer's disease - A European multicentre trial
    Winblad, B
    Bonura, ML
    Rossini, BM
    Battaglia, A
    CLINICAL DRUG INVESTIGATION, 2001, 21 (09) : 621 - 632
  • [6] Phase II Crossover Trial of Varenicline in Mild-to-Moderate Alzheimer's Disease
    Kim, Seong Yoon
    Choi, Seong Hye
    Rollema, Hans
    Schwam, Elias M.
    McRae, Tom
    Dubrava, Sarah
    Jacobsen, Janice
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2014, 37 (3-4) : 232 - 245
  • [7] Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease
    Yuqi Qiu
    Diane M. Jacobs
    Karen Messer
    David P. Salmon
    Cheryl L. Wellington
    Sophie Stukas
    Carolyn Revta
    James B. Brewer
    Gabriel C. Léger
    Brianna Askew
    Lia Donahue
    Stephen Kaplita
    Vladimir Coric
    Irfan A. Qureshi
    Howard H. Feldman
    Alzheimer's Research & Therapy, 17 (1)
  • [8] Memantine in the treatment of mild-to-moderate Alzheimer's disease
    Cosman, Kelly M.
    Boyle, Llsa L.
    Porsteinsson, Anton P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (02) : 203 - 214
  • [9] Solanezumab for the treatment of mild-to-moderate Alzheimer's disease
    Imbimbo, Bruno P.
    Ottonello, Simone
    Frisardi, Vincenza
    Solfrizzi, Vincenzo
    Greco, Antonio
    Seripa, Davide
    Pilotto, Alberto
    Panza, Francesco
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2012, 8 (02) : 135 - 149
  • [10] Y Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
    Ballard, Clive
    Atri, Alireza
    Boneva, Neli
    Cummings, Jeffrey L.
    Froelich, Lutz
    Luis Molinuevo, Jose
    Tariot, Pierre N.
    Raket, Lars Lau
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2019, 5 (01) : 164 - 174